 "Dr Reddy's gets 1 observation from USFDA after inspecting Hyderabad plant")
Dr Reddy's Laboratories on Friday said the US health regulator has issued a Form 483 with one observation after inspecting one of its formulation plants in Hyderabad.
Earlier in the day, the drug major had said that the US health regulator has issued a Form 483 with two observations after inspecting the facility.
"We wish to inform you that the US Food and Drug Administration (USFDA) investigator has subsequently issued a revised Form 483 with one observation only, in place of two observations intimated earlier," Dr Reddy's Laboratories said in a regulatory filing.
The company will address the said observation comprehensively within the stipulated timeline, it added.
As per the USFDA, Form 483 is issued to firm management at the conclusion of an inspection when investigators have observed any conditions that in their judgment may constitute violations of the Food Drug and Cosmetic Act and related Acts.
Dr Reddy's shares ended 4.66 per cent up at Rs 2,925.80 apiece on the BSE on Friday.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app